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1. Introduction 
Over the past four decades the incidence of oesophageal cancer has increased more rapidly 
than that of any other solid tumour in the Western World. This rise reflects the emergence of 
oesophageal adenocarcinoma as the most common pathological type. Despite this growing 
incidence, progress towards early detection and treatment has been slow and mortality 
figures have remained dismal – Cancer Research UK quotes overall one and five year 
survival rates of just 28% and 8% respectively.(CrUK, 2010) As a result, oesophageal cancer 
repreasents a real and growing public health problem and urgent action is required to 
improve detection and facilitate early intervention, ideally at a pre-malignant stage. 
Most oesophageal adenocarcinoma develops following a well recognised series of cellular 
changes secondary to a multifactorial aetiology. In the classically described pathway there is 
initially a metaplastic change in the epithelial lining of the oesophagus (Barrett’s 
oesophagus) which then progresses to ‘low-grade‘ and then ‘high-grade‘ dysplasia. As 
many as 30% of patients newly diagnosed with high-grade dysplasia may already have a 
coexistent invasive cancer, and between 5-60% of patients will develop cancer during 
surveillance over 1-7 years. 
To date there is no early diagnostic test which can enable instantaneous accurate diagnosis 
of dysplasia. Clinicians are advised to take random biopsies from areas of Barrett’s 
oesophagus in order to identify dysplasia, but even histological assessment of dysplasia is 
subjective and can be unreliable. As a result, significant dysplastic change (or even 
intramucosal cancer) may be missed. In addition, as dysplasia (the premalignant lesion) is 
difficult to identify, screening for early oesophageal cancer / high-grade dysplasia cannot 
currently be recommended, and as a consequence, oesophageal tumours present late and so 
have a poor prognosis. 
The early recognition of high-grade dysplasia is paramount to enabling a successful 
treatment strategy. Surgery is one option for patients with confimred HGD, however the 
emergence of multiple endotherapies over the past 20 years have demonstrated the ability to 
cure focal high-grade dysplasia, thus preventing progression to invasive malignancy. In this 
chapter we will discuss the accuracy of endoscopic and histological diagnosis of dysplasia 
and will consider novel endoscopic adjuncts which may improve endoscopic sensitivity. We 
will then discuss the endoscopic therapeutic options that are available for management of 
dysplastic Barrett’s oesophagus and will propose a endotherapy algorithm for use in 
specialist Barrett’s surveillance centres. 
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2. Endoscopic detection of Barrett’s oesophagus 
Barrett’s oesophagus is most often identified incidentally in patients who are undergoing an 
upper endoscopy for investigation of reflux symptoms. Barrett’s oesophagus has a classical 
endoscopic appearance of ‘salmon pink’ columnar mucosa arising proximally from the 
oesophago-gastric junction (OGJ), often with characteristic ‘tongue’ extensions. There may 
also be readily identifiable islands of columnar mucosa. Following endoscopic recognition, 
the extent of proximal extension above the OGJ should be measured and documented, 
taking care to accurately identify any sliding hiatus hernia which may confuse this 
measurement. The diagnosis must then be confirmed / corroborated histologically by 
multiple pinch biopsies of the affected segment. When biopsies are obtained it is crucial that 
they originate from the oesophagus and that their site is recorded as accurately as possible. 
The ‘Prague C and M criteria’, defined by an International Working Group on Barrett’s 
oesophagus, offers a validated method of classifying Barrett’s based on its endoscopic 
appearance. (Sharma et al., 2006b) The extent of circumferential involvement in centimetres 
from the OGJ should be recorded, as should the maximum length of the Barrett’s segment 
(including tongues of Barrett’s but excluding isolated ‘islands’). 
Difficulties arise in diagnosis particularly in ‘ultra-short’ segment Barrett’s oesophagus. The 
original description of Barrett’s oesophagus was of columnar metaplasia extending for at 
least 3cm from the OGJ. Although the risk of malignant progression is greater in long 
Barrett’s segments (>8cm), it is now recognised that shorter lengths, even below 3cm have 
malignant potential. (Hirota et al., 1999; Schnell et al., 1992; Sharma et al., 1997; May et al., 
2002) However, what appears endoscopically to be a short segment of Barrett’s oesophagus 
in the distal oesophagus or an irregular z-line may in fact represent intestinal metaplasia of 
the gastric cardia known as cardia intestinal metaplasia (CIM). (BSG Working Party, 2005) 
This can lead to misclassification of CIM as short segment Barrett’s. For this reason, the 
endoscopist has a crucial role in defining the exact position from which biopsies are taken to 
prevent misdiagnosis. 
3. Definition and clinical significance of Barrett’s dysplasia 
Dysplasia is defined as “an unequivocal neoplastic alteration of epithelium which has the 
potential to progress to invasive malignancy but remains confined within the basement 
membrane of the epithelium within which it arose.” (Shaheen and Ransohoff, 2002; Riddell 
et al., 1983) Dysplasia is classified as either low grade (LGD), or high grade (HGD) (often 
also termed high-grade intraepithelial neoplasia HGIN)), based on its histological 
appearances. As already described, HGD has a higher malignant potential than LGD and 
malignant transformation classically occurs through a stepwise progression of pathology 
from metaplastic Barrett’s oesophagus, to LGD, then HGD, and finally invasive 
adenocarcinoma. 
Understanding the pathogenesis and natural history of Barrett’s oesophagus is key to 
understanding the malignant potential and clinical significance of the various dysplastic 
stages. Surveillance studies have shown that the risk of developing adenocarcinoma varies 
between 0.4% and 1% per year (in the US and UK respectively). However, it is clear from 
cohort studies that not all Barrett’s oesophagus progresses to dysplasia. In fact, in most long-
term studies fewer than 10% of patients show evidence of progressive disease. (Schnell et al., 
2001a) Patients with Barrett’s oesophagus are thought to have a lifetime risk of developing 
oesophageal adenocarcinoma of 3-14% (approximately 0.5-1% per year following diagnosis). 
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(Shaheen et al., 2000; Drewitz et al., 1997) (Jankowski et al., 2000; Spechler et al., 2010; 
Shaheen and Richter, 2009; Jankowski et al., 2002) This represents an increased risk of 30-100 
fold compared to the general population. However, cancer rates in excess of 10% per year 
have been described in patients with HGD. (Shaheen and Richter, 2009) 
Several studies have also noted regression of disease in patients treated with acid 
suppression, and even complete resolution has been described. Similarly there is some data 
suggesting that anti-reflux surgery can improve the histological appearance of Barrett’s 
oesophagus, although it is not currently recommended for this purpose. (BSG Working 
Party, 2005). 
4. Endoscopic recognition of dysplasia 
Endoscopic recognition of dysplasia within Barrett’s oesophagus is difficult and unreliable, 
even for skilled endoscopists. A rigorous biopsy protocal such as that recommended by the 
British Society of Gastroenterologists (Box 1) is therefore necessary to identify any dysplastic 
change so that apropriate surveillance / endotherapy / surgery can be considered. Sites of 
biospy must be accurately recorded and when possible macroscopic lesions should be 
classified using the Paris classification (Box 2). 
 
 
Box 1. Biopsying Barrett’s oesophagus
 
Dysplasia is often macroscopically invisible. In patients with Barrett’s oesophagus, 
endoscopists are therefore advised to follow a rigorous biopsy protocol. The British 
Society of Gastroenterologists recommends the following: 
 
- Quadrantic biopsies for every 2cm of columnar lined oesophagus 
- Additional biopsies of macroscopically suspicious areas 
 
NB/ Even with strict adherence to this policy <5% of oesophageal mucosa is sampled. 
 
 
Relative sampling volume = 0.05% 
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Endoscopic recognition of gross mucosal abnormalities such as ulceration, nodularity, and 
erythema is relatively straightforward. The problem is that early neoplastic lesions are 
frequently flat and often have little or no visible mucosal abnormality. Only 50-70% of HGD 
can be identified by experienced endoscopists using white light endoscopy. This figure is 
lower for non-specialists and is considerably lower for the detection of LGD. In addition, 
more than 20% of intramucosal cancers may be missed endoscopically, even in specialist 
units. This is particularly concerning when it is considered that routine biopsy protocols 
used for Barrett‛s surveillance have been shown to miss up to 57% of early neoplastic 
lesions. (Vieth et al., 2004) 
As early neoplasia in Barrett’s oesophagus is a relatively rare finding, the lack of familiarity 
of most endoscopists with its typical appearances is a significant limiting factor in its 
detection. Knowledge of the appearance of these early lesions is therefore key to their early 
recognition. Figure 1 illustrates a range of mucosal abnormalities within segments of 
Barrett’s oesophagus which are consistent with early neoplastic change. 
 
  
Fig. 1a (left) illustrates a nodular area of what proved to be HGD in a tongue of Barrett’s 
oesophagus. 1b (right) illustrates multifocal nodular Barrett’s neoplasia. In this example 
clinicians must have a very high level of suspicion for the presence of invasive malignancy 
Another factor critical to endoscopic detection of dysplastic Barrett’s oesohagus is a 
systematic approach to mucosal inspection. The oesophagus may be cleaned using water or 
1% acetylcysteine to remove saliva and gastric refluxate and the oesophagus must be 
adequately distended by inflation. Special care must be taken in patients with a hiatus 
hernia as in these cases the distal extent of the Barrett’s segments can be difficult to identify 
meaning dysplasia at the oesophagogastric junction can be missed. In addition, clinicains 
should be aware that the majority of neoplastic lesions are located between 12 and 6 o’clock 
in the endoscopists view. (Curvers et al., 2008b) Importantly clinicians should also commit 
to investing considerable time to endoscopic inspection (as well as the time required for 
multiple biopsies), and endoscopy lists should be planned accordingly when patients with 
known Barrett’s oesophagus are attending for surveillance. 
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Biopsies should be taken (as per the BSG guidelines described in Box 1) and should start 
distally and work proximally to minimise any obstruction to the endoscopic view caused by 
bleeding. A description of the Barrett’s segment should then be recorded using the Prague 
C&M classification (see section 2) and positions of random biopsies and suspicious areas 
recorded meticulously. Where possible, visible macroscopic neoplasia should also be 
classified according to the Paris classification (Box 2). 
 
 
Several techniques have been developed to improve endoscopic recognition of dysplasia 
and intramucosal carcinoma in Barrett’s oesophagus. These aim to minimise sampling 
randomness and also facilitate targetted endoscopic resection in patients with histologically 
confirmed HGD / IMC. In addition, they aim to improve assessment of disease extent and 
minimise the incidence of missed synchronous tumours. 
4.1 High resolution endoscopy by expert endoscopists 
Modern high resolution endoscopes which generate up to one million pixel images 
(compared to the 300,000 pixel images of traditional scopes) have been shown to have a 
higher sensitivity for the detection of early Barrett’s neoplasia provided they are used by 
expert endoscopists.(Kara et al., 2005a; Kara et al., 2005c) These high definition endoscopes 
should be used in conjunction with a high definition television to further enhance the 
projected image quality and enable projection onto a larger screen without loss of image 
resolution. 
Studies have shown that up to 80% of patients referred to specialist units with biopsy 
proven HGD without visible abnormality will be found to have 1 or more visible 
abnormalities when endoscopy is repeated by an expert endoscopist using a high resolution 
endoscope. (10,12 from endoscopic work-up) (Kara et al., 2005a; Curvers et al., 2008d) 
4.2 Chromoendoscopy 
Chromoendoscopy utilises stains which bind selectively to different oesophageal mucosa 
and so can enable discrimination between non-dysplastic Barrett’s oesophagus and HGD / 
Box 2. Classification of visible early Barrett’s neoplasia
 
Visible macroscopic early neoplastic lesions in Barrett’s oesophagus are classified using 
the Paris classification. A description of the superficial (0) lesions is detailed below. 
 
0 Superficial lesions 
0-I              Protruding / polypoid lesions 
 0-Ip Pedunculated 
 0-Is Sessile lesions 
0-II          Non-protruding / non-excavated lesions 
 0-IIa Slightly elevated 
 0-IIb Completely flat 
 0-IIc Slightly depressed 
0-III          Excavated / ulcerated lesions 
 
Most dysplastic Barrett’s lesions are of superficial type (0-II). 
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adenocarcinoma. Staining and lesion defining agents utilised include methylene blue, indigo 
carmine, and acetic acid. Results from studies utilising this technique have been mixed 
citing problems such as an inability to uniformly coat the oesophageal mucosa with the 
stain, and excessive time necessary for stain spraying as particular concerns.(Shaheen and 
Richter, 2009; Lim et al., 2006; Ragunath et al., 2003) None of these techniques has been 
shown to consistently out-perform high resolution endoscopy in the detection of early 
neoplastic lesions.(Curvers et al., 2008c)  Chromoendoscopy is often both labour-intensive 
and operator-dependent and therefore although it may have a role when used in specialist 
centres by expert users, it is unlikely to develop a wider role in routine clinical practice. 
4.3 Narrow band imaging (NBI) 
NBI filters white light into blue and green wavelengths (at the push of a button) giving more 
accurate images of the mucosal and vascular patterns in the oesophageal lining. This 
increased superficial imaging of the oesophagus (without the need for staining) can be used 
to identify dysplastic lesions within Barrett’s segments.(Kara et al., 2006a) In the hands of 
experienced users the technique has shown promise however, results have been 
mixed.(Sharma et al., 2006a; Curvers et al., 2008a) A recent trial from Holland shows no 
diagnostic benefit from either NBI or chromoendoscopy.(Curvers et al., 2008a) However, 
data on the accuracy of NBI is still inconclusive and results of ongoing mulitcentre 
randomised controlled trials are awaited. 
4.4 Autofluorescence imaging (AFI) 
Following excitation with short wavelengths of light many endogenous tissues emit 
fluorescence radiation which can be measured using fluorescence spectroscopy. Metaplastic 
and dysplastic Barrett’s oesohagus have been shown to emit slightly different fluorescence 
spectra enabling the technique to be used as a mechanism to discriminate between the two 
pathologies. AFI appears to improve the detection of early Barrett’s neoplasia when used in 
combination with high resolution endoscopy, although the false positive rate is relatively 
high.(Curvers et al., 2008b; Kara et al., 2005b; Kara et al., 2006b) Further studies are clearly 
indicated to truely assess the potential long-term role for AFI. 
4.5 Optical coherence tomography (OTC) 
OCT is analogous to ultrasound but can produce higher quality images as it relies on 
scattering of near infrared light as opposed to reflection of sound waves. OCT can obtain 
cellular images of sub-epithelial tissue through differences in their light scattering properties 
and avoids the need for exogenous contrast material.  
In a study of 55 patients with Barrett‛s oesophagus, OCT was shown to delineate between 
HGD and oesophageal adenocarcinoma with a sensitivity of 83% and a specificity of 
75%.(Evans et al., 2006) Similarly, a study of 33 patients demonstrated a diagnostic accuracy 
of 78% for the identification of dysplastic Barrett’s oesophagus but with considerable user 
discrepency (56% to 98%). (Isenberg et al., 2005) Further clinical evaluation is required to 
fully assess the performance of OCT and assess the feasibility of introducing this promising 
diagnostic tool into routine clinical practice. 
4.6 Confocal microscopy (CM) 
CM magnifies the mucosa by more than 1000 fold producing images with 1-2 µm spatial 
resolution and allowing real time visualisation of cellular structures. Kiesslich et al studied 
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63 patients with Barrett‛s oesophagus using white light endoscopy and confocal microscopy. 
Intravenous fluorescein was administered to generate vascular contrast and at sites of 
neoplasia could be seen to disperse within the lamina propria due to irregular 
neovascularisation. Accuracy of CM was found to be 97.4% (sensitivity 93%, specificity 
98%). (Kiesslich et al., 2006) In another study by Dunbar et al, CM was shown to help target 
biopsies to areas of neoplasia, doubling diagnostic yield per biopsy taken, and avoiding the 
need for biopsy in two thirds of patients undergoing surveillance. However, no overall 
increase in neoplasia was identified when CM targetted biopsying was compared to random 
quadrantic random biopsies every 2cm. 
Confocal microscopy is an expensive technique and requires the use of exogenous contrast. 
It has already demonstrated potential in early diagnosis of Barrett‛s neoplasia although the 
excellent results reported by some studies have not been universally matched. (Pohl et al., 
2008) Further studies are required before this technique can be reccommended for 
widespread use. 
4.7 Labelling of biomarkers 
Molcular biomarkers associated with neoplastic cells can be labelled using a specifically 
targetted probe molecule which has been tagged with a visual agent such as a fluoresecent 
dye. (Pierce et al., 2008) (Thekkek et al., 2011) The probe molecule selectively binds to the 
biomarker so that areas of neoplasia can be visualised with a high signal to noise ratio. 
Lu et al identified a cell surface peptide specific to adenocarcinoma which they labelled 
using a fluorescein-tagged antibody delivered topically. The oesophagus was then washed 
to remove any unbound antibody and a fluorescence endoscope was used to visualise  
neoplastic disease. (Lu and Wang, 2008) 
Other similar studies have used a range of potential biomarkers with similar effect. This is 
clearly a very promising technique for the detection of early neoplasia but further on-going 
work is necessary to identify novel molecular targets in order to improve sensitvity and 
specificity before widespread implementation of the technique can be contemplated. 
4.8 Raman spectroscopy 
Raman spectroscopy is an optical diagnostic technique which has shown considerable 
potential for early diagnosis of a variety of malignant disease states including oesophageal 
neoplasia. Raman spectroscopy measures the molecular-specific, inelastic scattering of laser 
light within tissue in order to generate a unique molecular ‘fingerprint’. Normal, dysplastic 
and cancerous tissues have differing biochemical cellular components leading to 
characteristic spectral differences which can be analysed. Laboratory based Raman 
spectrometers are capable of discriminating between eight pathological groups in the distal 
oesophagus (including Barrett’s metaplasia, HGD and adenocarcinoma) with sensitivities 
between 73% and 100%. (Kendall et al., 2003) Several groups are currently investigating 
the potential for endoscopic Raman spectroscopy using a fibre-optic Raman probe. Fibre-
optic Raman sectroscopy has already demonstrated encouraging results following in vivo 
trials in the stomach, bladder and cervix. Although some way off clinical implementation 
in the oesohagus, in vivo and ex vivo results are promissing and this technique may 
become widely available in the short to medium term to enable instant endoscopic 
diagnosis of dyslasia (without the need for biopsy) and to facilitate immediate, targetted 
endotherapy. 
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5. Barrett’s oesophagus surveillance 
As endoscopic recognition of dysplasia remains limited at present, a policy of regular 
endoscopic surveillance, in conjunction with a rigourous biopsy regimen, is recommeded. 
The frequency of surveillance endoscopy depends predominantly on the presence and 
degree of dysplasia identified, and also to a lesser extent on patient age, comorbidity and 
patient preference. 
Several retrospective studies have demonstrated a survival benefit for patients with cancers 
detected by surveillance endoscopy rather than following symptom investigation. (Streitz et 
al., 1993; Peters et al., 1994; van Sandick et al., 1998; Fountoulakis et al., 2004; Corley et al., 
2002) However, many other studies have failed to show this. (Wong et al., 2010) The 
Barrett’s Oesophagus Surveillance Study (BOSS) is a multi-centre randomised control trial 
currently recruiting patients throughout the UK. In this study patients are randomised to 
either ‘endoscopy at need’ (no routine surveillance), or repeat OGD combined with BSG 
biopsy regimen every two years for a total of ten years. The study aims to define the 
objective value of endoscopic surveillance and the most appropriate surveillance protocol. 
Despite the current lack of high level evidence, most clinicians elect to follow up patients 
with Barrett’s oesophagus provided the pros and cons of surveillance have been fully 
discussed with the patient and they subsequently wish to proceed with surveillance 
endoscopy. Clearly, this approach is not suitable for all-comers, and management should 
therefore be individualised appropriately. For example, long-term follow-up of elderly 
patients who are unfit for intervention is not usually recommended. 
Where surveillance is deemed appropriate BSG guidelines recommend 2-yearly endoscopy 
using a comprehensive biopsy protocol. (BSG Working Party, 2005) Quadrantic biopsies are 
recommended every 2cm of Barrett’s oesophagus, with more targeted biopsies of any raised 
or suspicious looking areas (Box 1). Patients should have their reflux treated with a proton 
pump inhibitor so that the presence of oesophagitis does not complicate the histological 
identification of dysplasia. Patients with Barrett’s oesophagus who are not enrolled in 
endoscopic surveillance should also receive proton pump inhibitor (PPI) therapy The 
effectiveness and dosage of PPI therapy with and without aspirin for the prevention of 
progression of Barrett’s oesophagus is being addressed in the Aspirin Esomeprazole 
Chemotherapy Trial (ASPECT) in the united Kingdom. 
For those patients undergoing routine endoscopic surveillance, the risk of developing 
adenocarcinoma is approximately 1% a year in the UK, and about half this figure in the US. 
(Jankowski et al., 2002) Critcially when dysplasia has been identified on endoscopy every 
effort must be made to ensure that the correct diagnosis has been reached and an 
appropriate management strategy should then be formulated. 
6. Importance of histological / radiological assessment 
Accurate histological diagnosis is essential when assigning treatment strategies for Barrett’s 
dysplasia and early Barrett’s malignancies. Histopathologists can have difficulty 
differentitating HGD from LGD, and also HGD from early invasive (T1) carcinoma based on 
point biopsy appearances alone. In recent years endoscopic resection (ER) has become 
recognised as not only a potentially curative therapy, but also a vital diagnostic technique 
(section 7.1.1). The role of ‘diagnostic’ ER is expanding as pathologists realise the 
importance of accurate assessment and grading of early tumours. 
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The current BSG guidelines from 2005 do not recognise the diagnostic role of ER. However, 
new guidelines are currently being formulated by an international consensus group the 
‘Barrett’s Dysplasia and Cancer Taskforce’ (BAD CAT). These will stress the need for 
extremely accurate assessment of the presence and depth of invasive cancer and will 
recommend confirmation using ER, as well as (when indicated) further staging using 
endoscopic ultrasound (EUS) (which is known to be poor at differentiating between T1a and 
T1b tumours but is sensitive for lymph node metastases), and possibly PET-CT. 
Recent studies have demonstrated the importance of accurate staging of early (T1) tumours. 
T1a lesions (confined to the mucosa) have a very low incidence of lymphatic invasion (<5%) 
whereas, invasion into the submucosa (T1b) is associated with lymphatic spread in 20-45% 
of cases. New evidence has suggested that the distinction between T1sm1 and T1sm2 (i.e. 
between the upper 1/3 and lower 2/3 of the submucosa) may be particularly significant as 
the risk of lymphatic spread appears to significantly increase in T1sm2 tumours. This 
distinction is vital as surgical oesophagectomy and lymphadenectomy provide the only 
chance of cure for patients with lymphatic spread, whereas endoscopic therapy is 
potentially curative in those without lymphatic invasion. 
As histopathological diagnosis and grading of dysplasia is difficult and subjective, any 
suggestion of dysplasia should be reviewed by expert pathologists at an MDT prior to 
initiation of a management plan. In cases where exact histopathological diagnosis proves 
difficult clinicians should have a low threshold for ‘diagnostic’ endoscopic resection to aid 
histological classification. This may be of particular benefit in distinguishing between HGD 
and early invasive (T1) carcinoma, and in accurately T-staging these early cancers. 
7. Endoscopic therapies for HGD and IMC 
Once an accurate diagnosis has been made and corroborated by consensus opinion in an 
MDT, a management plan can be formulated. All patients should be commenced on high 
dose PPI therapy. Subsequent management is currently subject to significant debate but is 
largely dependent on the degree of dysplasia, patient comorbidity and patient preference. 
Recent developments have led to potentially curative endoscopic treatments for HGD and 
early mucosal cancer. Many of these techniques are relatively novel and are not supported 
by highest level evidence (RCTs). BSG and American College of Gastroenterology (ACG) 
guidelines from 2005 and 2008 respectively are now somewhat out-of-date when considering 
the management of advanced dysplasia / early cancer. However, the management of LGD 
has not altered in recent years as a simple ‘number needed to treat’ analysis confirms that 
the limited risks posed by LDG (in isolation), do not warrant the cost and morbidity imposed 
by endoscopic therapies. 
The management of HGD and intramucosal cancer (T1a) is currently hotly debated and new 
guidelines are awaited (BAD CAT consensus). It is clear that management policies must be 
individualised according to the nature and severity of disease and the age and comorbidity 
of the patient being treated, and all management decisions must be discussed at a specialist 
cancer MDT. 
There are two main forms of endoscopic therapy available to treat HGD and intramucosal 
tumours – endoscopic resection and endoscopic ablation. These techniques aim to destroy the 
lining of the oesophagus and promote regenerative re-growth of normal squamous mucosa. In 
order for this to occur, (as opposed to columnar re-growth) some of the superficial squamous 
lined ducts must survive the process. Techniques for mucosal ablation include photodynamic 
therapy, thermal ablation, radiofrequency ablation and argon plasma coagulation. 
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8. Endoscopic resection 
Endoscopic mucosal resection (EMR) describes any technique which removes a complete 
area of mucosa. However, the term is somewhat misleading and many authors recommend 
a switch to the term ‘endoscopic resection’ (ER), as the aim of EMR should involve complete 
excision of the mucosal and submucosal layers down to the muscularis propria. 
The technique involves raising an area of mucosa using suction or by submucosal injection, 
and then snaring it off (in a similar manner to a colonic polyp). It is a useful technique for 
removing focal areas of HGD or early cancer, and as well as being therapeutic, can provide 
important diagnostic information. 
 
 
Fig. 2. Endoscopic resection of an early invasive cancer 
8.1 Diagnostic endoscopic resection 
Although not yet recognised by BSG guidelines, ER has now become an important 
diagnostic technique in patients with HGD / early cancer. ER preserves tissue architecture 
so that a full histopathological assessment can be made. (Odze and Lauwers, 2008) An ER 
specimen can be more easily orientated than a mucosal point biopsy and should contain a 
significant portion of submucosa allowing accurate assessment of the depth of invasion of 
IMC. A retrospective study of 150 EMR specimens (focal lesions) found that following 
analysis of EMR specimens, initial diagnoses (based on point mucosal biopsies) where 
changed in 49% of cases, leading to a change in management plan in 30%. (Peters et al., 
2008) Mino-Kenudson et al recently demonstrated that interobserver reporting agreement 
between pathologists was improved when reporting EMR specimens rather than point 
biopsies, particularly when differentiating between intramucosal and submucosal 
carcinoma – a key distinction when planning a treatment strategy. (Mandal et al., 2009) ER 
specimens also enable improved assessment of other important prognostic factors such as 
the grade of cellular differentiation and the presence of lymphovascular invasion. ER has 
been shown to be the best technique for assessment of visible mucosal abnormalities within 
Barrett’s oesophagus. However, the technique does have complications, and these must be 
considered when performing an ER for diagnostic purposes. 
8.1.1 Therapeutic ER 
As a therapeutic technique, oesophageal ER has been assessed in a number of large studies, 
although no randomised controlled trials currently exist. Its first description in HGD and 
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early mucosal cancers in Barrett’s oesophagus was published in 2000, although ER was 
described for early oesophageal SCC as far back as the early 1990s. 
A recent study reported that ER achieved remission in 82.5% of patients with HGD. 
However, over a 12 month period of follow-up, metachronous lesions or disease recurrence 
were identified in 14% of patients, necessitating re-treatment. A further study using ER, 
photodynamic therapy (PDT) or a combination, showed overall complete disease remission 
in 98% of patients, but metachronous cancer was identified in 31% over a 34 month post 
treatment surveillance period. (Pech et al., 2007) 
Extensive, multifocal disease is more difficult to manage endoscopically using ER. Several 
studies have described circumferential ER of extensive Barrett’s segments but, despite 
experienced hands, these extensive resections have been associated with significant 
complication rates (bleeding 33%, strictures 17-26% and perforation 3%) and large studies 
with prolonged follow-up have not been conducted. (Pech et al., 2007; Seewald et al., 2003)In 
addition, significant recurrence rates have been reported and in up to 25% of cases, complete 
resection of the Barrett’s segment was impossible despite several staged attempts at 
treatment. (Pech et al., 2007) 
As discussed previously, oesophageal lesions that invade into the lamina propria but are 
confined to it (do not invade the submucosa) T1m1-3 (T1a) lesions have a 5% chance or less 
of nodal involvement. Recent data have suggested that shallow mucosal invasion T1sm1 also 
has a significantly lower risk of nodal metastases than other grades of submucosal invasion. 
(Prasad et al., 2007; Gondrie et al., 2008) Whereas deeper invasion into the submucosa 
(T1sm2-3) sees this risk rise to 20-45%. (Peyre et al., 2008) In early cancers with a low risk of 
lymphatic spread, ER offers a curative, minimally invasive treatment option, which may be 
particularly appropriate in older patients at higher risk of operative morbidity / mortality. 
Average 3-year survival rates of more than 80% have been reported for IMC treated by ER. 
In recent years there has been a move towards combination therapy in an attempt to reduce 
recurrence rates. Areas of focal dysplasia (or IMC) could be treated with ER, followed by 
complete ablation of the entire Barrett’s segment using APC, PDT, or RFA. 
8.2 Mucosal ablation therapy 
Ablation techniques aim to destroy the lining of the oesophagus and promote regenerative 
growth of normal squamous mucosa. Techniques for mucosal ablation include photodynamic 
therapy, thermal ablation, radiofrequency ablation and argon plasma coagulation, all of 
which must be used in combination with acid suppression. 
There are so far no randomised trials comparing these treatments against each other. In 
addition, the natural history of regenerated squamous epithelium is not fully known, 
(although there certainly appears to be a substantial reduction in malignant potential) so 
further long-term studies are still awaited. (Overholt et al., 2005) 
8.2.1 Radiofrequency ablation 
RFA is a relatively new technique which can be used to ablate circumferential (HALO360) or 
focal (HALO90) Barrett’s oesophagus. Circumferential ablation is performed using a balloon 
to apply radiofrequency energy evenly to the oesophageal lining. 
The length of the Barrett’s segment is first measured endoscopically. N-acetylcysteine is 
then used to wash saliva, mucus and gastric juice from the oesophagus and a guidewire is 
placed into the gastric antrum. The endoscope is removed and a sizing balloon is inserted 
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over the guide wire and inflated once in the distal oesophagus. In long segment Barrett’s 
oesophagus several measurements are taken and subsequently, an appropriately sized 
ablation catheter is selected (based on the smallest oesophageal diameter measurement). The 
catheter is then passed over the guide wire and positioned at the proximal extent of the 
Barrett’s segment. The endoscope is re-passed to ensure correct positioning of the catheter 
and the balloon is then inflated and a standardised dose of energy is delivered (which has a 
power density sufficient to ablate down to the muscularis mucosae, 700-1000µm deep). After 
a short period of treatment (<5s) the catheter is passed distally to the next portion of the 
oesophagus to be treated, trying to minimise overlap between zones by endoscopic 
visualisation. Once the entire Barrett’s segment has been ablated the catheter is removed 
and the endoscope is reinserted in order to debride the ablated mucosa. The procedure is 
then repeated so that the whole Barrett’s segment receives two treatments. 
Complications are rare but include significant bleeding (1-2%), stricture formation (6%) and 
perforation (very rare). (Shaheen et al., 2009) Repeat OGD is recommended after 2 – 3 
months and any residual focal Barrett’s oesophagus can then be treated using HALO90 RFA. 
The only RCT, by Shaheen et al in 2009, demonstrated successful resolution of dysplastic 
Barrett’s oesophagus following treatment with RFA.(Shaheen et al., 2009) Complete 
eradication of LGD was seen in 90.5% (ablation group) compared to 22.7% (control group) 
(P<0.001). Complete eradication of HGD occurred in 81.0% (ablation group) versus 19.0% 
(control group) (P<0.001). RFA also decreased the likelihood of disease progression (3.6% vs. 
16.3%, P=0.03) and cancer (1.2% vs. 9.3%, P=0.045). 
Recent NICE guidelines (June 2010) recommend that clinicians in the UK consider 
endoscopic ablation therapy (preferentially RFA) along with EMR, for treatment of HGD 
and IMC, particularly in patients not suitable for oesophagectomy. 
8.2.2 Photodynamic therapy 
Porfimer sodium photodynamic therapy (PDT) has been approved by the US Food and 
Drug Administration (FDA) and (provisionally) by NICE for treatment of HGD in Barrett's 
oesophagus. 
The procedure involves systemic (intravenous) administration of a photosensitising agent 
(porfimer sodium) which is retained selectively by dysplastic cells. After about 48 hours the 
patient undergoes an upper endoscopy and a laser is used to excite a cytotoxic reaction in 
dysplastic Barrett’s cells, leading to their destruction. There is now strong evidence that PDT 
can prevent the progression of disease in patients with Barrett’s HGD. (Overholt et al., 2007) 
A five year randomised multicentre trial by Overholt et al demonstrated that PDT was 
significantly more effective at eradicating HGD than omeprazole only (odds ratio 2±0.7). It 
also significantly lengthened the time taken to progress to malignancy and reduced the 
overall risk of malignant progression by half. (Overholt et al., 2007) Following PDT, patients 
are required to continue life-long surveillance, and repeat ablation may become necessary. 
Side-effects of PDT include nausea and chest pain in the first day or two after treatment. In 
the longer term, oesophageal strictures may occur in up to a quarter of patients. 
Oesophageal perforation has also been described (very rarely). In addition, due to the 
photosensitising affect of porfimer sodium, patients are required to minimise light exposure 
to their skin for up to 4-6 weeks after the treatment. 
Several trials in Europe have used 5-ALA as the photosensitising agent in an effort to reduce 
skin sensitivity and oesophageal strictures. However, additional blood pressure and cardiac 
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complications have been reported with 5-ALA and further work is therefore required to 
clarify the most effective drug with the least side-effects. 
8.2.3 Argon plasma coagulation 
APC (the most commonly used form of thermal ablation) uses a jet of ionized argon gas 
(plasma) directed through an endoscopic probe to ablate short segments of Barrett’s or areas 
of persistent disease following other ablative treatment. A trial by Pech et al retrospectively 
assessed disease recurrence in patients treated by EMR with or without subsequent APC 
ablation of the residual Barrett’s segment. Rates of recurrence fell from 33.3% to 17.6% with 
the inclusion of APC ablation. Other studies support these results and confirm low 
complication rates. 
9. Buried glands 
In some cases following ablative therapy for Barrett’s oesophagus, a normal squamous 
epithelium may re-grow over a portion of Barrett’s tissue. Endoscopically this appears 
normal, but these buried Barrett’s glands may retain malignant potential. Endoscopists must 
be aware of this when surveying patients who have previously undergone ablative 
endotherapy and for this reason life-long endoscopic surveillance is recommended for these 
patients, even in the absence of residual Barrett’s oesophagus. 
10. Oesophagectomy 
HGD is associated with early invasive malignancy in up to 30% of cases, and carries a 
significant long-term chance of malignant progression. In addition, recurrence rates 
following ablative therapies are significant and endoscopic surveillance must be lifelong. 
For these reasons, surgical excision of the entire Barrett’s segment must still be considered 
the ‘gold standard’ treatment for young, fit patients with multifocal HGD. 
Oesophagectomy is the only potentially curative treatment once lymph nodes are involved. 
It also aims to remove the entire Barrett’s segment minimising the chance of recurrence or 
missed metachronous lesions. Recent centralisation of cancer services has improved 
operative mortality to 5% or less in most specialist units. However, for patients without 
proven invasive cancer, this still remains a considerable risk. In addition, morbidity 
following oesophagectomy remains considerable although minimally invasive and vagal 
sparing surgery aims to minimise this and improve long-term functional outcomes. (Ell et 
al., 2007) 
11. Management of low-grade dysplasia 
Patients with LGD should undergo repeat endoscopy with adherence to a ‘gold standard’ 
biopsy regimen 8-12 weeks after the commencement of PPI therapy. A repeat endoscopy 
should then be performed at 6 months, and if LGD persists, endoscopy should be repeated 
6-monthly unless regression to normal Barrett’s or squamous epithelium occurs, at which 
time surveillance can be reduced to 2 yearly intervals. (BSG Working Party, 2005) 
In some cases of multifocal, persistent LGD, endoscopic mucosal ablation therapy could be 
considered, particularly if there is a strong patient desire for intervention (BSG Working 
Party, 2005) (although evidence for this statement is limited and widespread treatment of 
LGD is not cost-effective and is not recommended). 
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12. Management of high-grade dysplasia / intramucosal cancer 
Data from case series suggest that up to 10% of patients with Barrett’s oesophagus develop 
HGD, and that HGD may be associated with a focus of adenocarcinoma in up to 30% of 
patients. Several studies also have described high rates of progression to malignancy – 
annual rates of progression of 2.2%, 4% and 11.8% have been described recently. (Schnell et 
al., 2001b; Buttar et al., 2001; Reid et al., 2000b) In addition, the average time to progression 
from HGD to cancer is known to be short, typically around 24 months, (ranging from 6-43 
months), (although, in most cases, HGD remains stable without progression, or may even 
regress). (BSG Working Party, 2005) 
In confirmed cases of IMC, clinicians must not only consider T-stage, but also other 
important prognostic indicators including the grade of cellular differentiation and the 
presence of lymphatic or vascular invasion, when formulating a management strategy. 
It is now clear that ER has an important diagnostic role in the determining these important 
prognostic indicators. Endoscopic ultrasound (EUS) is also important in intramucosal cancer 
to assess for the presence of early nodal metastases. EUS has been shown to be substantially 
more accurate than CT for detecting nodal metastases and the role of CT in investigation of 
intramucosal tumours is probably limited. PET-CT is a more reliable means of assessing the 
presence of distant metastasis which would circumvent the need for surgery and necessitate 
palliative therapy.  
EUS is known to be poor at distinguishing between T1a and T1b tumours (33-85% accuracy) 
and importantly, under-diagnosis of T1b lesions is common. (May et al., 2004; Zuccaro et al., 
2005). ER assessment is much more reliable but may fail to completely excise the submucosa 
making exact distinction between T1sm1 and T1sm2 difficult. Frequently pathologists use the 
measured depth of invasion in micrometers to differentiate the two. However, there is a 
paucity of published data correlating measured depth of submucosal invasion with likelihood 
of lymph node metastasis. Currently the role of endoscopic submucosal dissection (ESD) in 
the oesophagus is unclear and further trials are awaited. 
If endoscopic therapy is to be considered ahead of surgery for early oesophageal tumours 
and HGD, a number of important considerations should be satisfied (Box 3). Similarly, if 
surgery is to be considered in cases where there is no overt evidence of lymphatic spread, 
complication rates must be low. Many papers continue to quote historic rates of mortality 
following oesophagectomy. It is important when contemplating treatment options to 
compare up-to-date data which reflects recent improvements in operative outcomes 
(mortality and morbidity) since surgical centralisation took place. 
 
 
Box 3. Important considerations when considering the role of endoscopic 
therapy.  
 
- There must be no (or minimal) under-staging of disease. 
- Practitioners must be adequately skilled. 
- Recurrence must be identified early and there must be a means of treating it. 
- Patients must understand that endoscopic therapy is less likely to provide a 
“cure” than surgical treatment. 
- Patients must understand that they will require long-term surveillance, (unlike 
following surgery). 
- Complication rates (morbidity and mortality) must be low. 
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12.1 Multifocal HGD 
Patients with multifocal disease are at a significant risk (up to 30%) of an undetected 
metachronous cancer and therefore warrant definitive treatment. Surgical oesophagectomy 
should still be considered as the first line treatment option for patients with persistent HGD 
provided they are deemed low operative risk and have a long life expectancy. Surgery must 
be carried out in specialist centres where mortality rates do not exceed 5%. 
Those patients with confirmed persistent multifocal HGD who are deemed unfit for an 
oesophagectomy should receive ER to visible areas of HGD and subsequent ablation of the 
entire Barrett’s segment. Several ablative treatments (using different modalities) may be 
required to establish complete remission. Patients will subsequently require lifelong 
endoscopic surveillance. 
12.2 Focal HGD 
Patients should be initially managed by ER of the affected area to confirm the diagnosis and 
exclude early malignancy. Those with a limited area of histologically confirmed HGD 
should undergo subsequent mucosal ablation of the whole Barrett’s segment. Young 
patients who are fit for major surgery should be considered for oesophagectomy. 
Clinicians should have a high level of suspicion for cancer and if suspected appropriate 
investigations e.g. endoscopic ultrasound and PET-CT should be considered. Nodularity on 
endoscopy should particularly raise concern although occult intramucosal tumours can 
occur with no visible mucosal abnormality.  
Patients with HGD should initially undergo three monthly endoscopy with quadrantic 
biopsies every 1cm – shown to half the chance of missing oesophageal adenocarcinoma 
compared to 2cm biopsies. (Reid et al., 2000a) Jumbo biopsies (using large capacity forceps) 
can also be taken in this setting. 
12.3 Intramucosal carcinoma 
All patients with confirmed oesophageal cancer should undergo formal tumour staging to 
establish the presence or absence of distant or locoregional metastases. Surgery should be 
regarded as the treatment of choice for patients deemed fit enough to tolerate 
oesophagectomy. Patients with high operative risk with T1a (and possibly T1sm1) tumours 
confirmed on ER should be considered for endoscopic therapy (ER followed by ablation). 
13. Summary 
All treatment decisions should be discussed in a multidisciplinary team meeting once every 
effort has been made to ensure the correct diagnosis has been reached. Patients (and 
families) should be fully informed and involved in the decision making process. All surgical 
and endoscopic procedures should be performed by specialists in recognised cancer units. 
ER should be used as a potentially curative treatment for IMC and focal HGD, and also has 
an emerging role in aiding histological diagnosis. Following ER the goal should be to ablate 
the entire Barrett’s segment. Due to the technical difficulties and costs associated with PDT, 
its role is increasingly being superseded by that of RFA. Following initial ablative therapy, 
further treatments (using the same or different treatment modalities) should be given in an 
attempt to destroy any remaining metaplastic / dysplastic epithelium. The aim should be 
complete squamous regeneration, however even if successful, surveillance should be life-
long as glands with malignant potential may persist burried beneathe the regenerated mucosa. 
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This combination of endoscopic resection and ablation of high-grade dysplasia and 
intramucosal cancer offers alternative therapeutic options to those unsuitable or unwilling 
to contemplate radical surgical excision. This combination endotherapy has been shown to 
provide long-term survival in patients with HGD and IMC and it is possible that this 
management strategy may soon become the treatment of choice for all patients with HGD. 
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